{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:17:10Z","timestamp":1793575030409,"version":"4.5.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["ZIA ES101081"],"award-info":[{"award-number":["ZIA ES101081"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["ZIA AR041215-02"],"award-info":[{"award-number":["ZIA AR041215-02"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biomedical Research Centre Funding Scheme"},{"DOI":"10.13039\/501100008741","name":"European League Against Rheumatism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American College of Rheumatology"},{"name":"Social & Scientific Systems"},{"DOI":"10.13039\/100000066","name":"NIEHS","doi-asserted-by":"publisher","award":["HHSN273201600011C"],"award-info":[{"award-number":["HHSN273201600011C"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Czech Ministry of Health, Conceptual Development of Research Organization","award":["00023728"],"award-info":[{"award-number":["00023728"]}]},{"name":"Institute of Rheumatology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The ACR-EULAR Myositis Response Criteria (MRC) were developed as a composite measure using absolute percentage change in six core set measures (CSMs). We aimed to further validate the MRC by assessing the contribution of each CSM, frequency of strength vs extramuscular activity improvement, representation of patient-reported outcome measures (PROM), and frequency of CSM worsening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from adult dermatomyositis\/polymyositis patients in the rituximab (n\u2009=\u2009147), etanercept (n\u2009=\u200914), and abatacept (n\u2009=\u200919) trials, and consensus patient profiles (n\u2009=\u2009232) were evaluated. The Total Improvement Score (TIS), number of improving vs worsening CSMs, frequency of improvement with and without muscle-related CSMs, and contribution of PROM were evaluated by MRC category. Regression analysis was performed to assess contribution of each CSM to the MRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 412 adults with dermatomyositis\/polymyositis, there were 37%, 24%, 25%, and 14% with no, minimal, moderate, and major MRC improvement, respectively. The number of improving CSMs and absolute percentage change in all CSMs increased by improvement category. In minimal-moderate improvement, only physician-reported disease activity contributed significantly more than expected by MRC. Of patients with at least minimal improvement, 95% had improvement in muscle-related measures and a majority (84%) had improvement in PROM. Patients with minimal improvement had worsening in a median of 1 CSM, and most patients with moderate-major improvement had no worsening CSMs. Physician assessment of change generally agreed with MRC improvement categories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The ACR-EULAR MRC performs consistently across multiple studies, further supporting its use as an efficacy end point in future myositis therapeutic trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead110","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T07:57:01Z","timestamp":1678348621000},"page":"3672-3679","source":"Crossref","is-referenced-by-count":9,"title":["Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis\/polymyositis therapeutic trials and consensus profiles"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-597X","authenticated-orcid":false,"given":"Didem","family":"Saygin","sequence":"first","affiliation":[{"name":"Section of Rheumatology at University of Chicago and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh , Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0595-6533","authenticated-orcid":false,"given":"Hanna","family":"Kim","sequence":"additional","affiliation":[{"name":"Juvenile Myositis Pathogenesis and Therapeutics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health (NIH) , Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Douglas","sequence":"additional","affiliation":[{"name":"Social & Scientific Systems, Inc , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Erman","sequence":"additional","affiliation":[{"name":"Social & Scientific Systems, Inc , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Wilkerson","sequence":"additional","affiliation":[{"name":"Social & Scientific Systems, Inc , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"McGrath","sequence":"additional","affiliation":[{"name":"Social & Scientific Systems, Inc , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V","family":"Oddis","sequence":"additional","affiliation":[{"name":"Section of Rheumatology at University of Chicago and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh , Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9212","authenticated-orcid":false,"given":"Ingrid E","family":"Lundberg","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A","family":"Amato","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garc\u00eda-De La Torre","sequence":"additional","affiliation":[{"name":"Hospital General de Occidente de la Secretar\u00eda de Salud and Universidad de Guadalajara, Department of Immunology and Rheumatology , Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-1288","authenticated-orcid":false,"given":"Hector","family":"Chinoy","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Manchester Biomedical Research Centre, Division of Musculoskeletal and Dermatological Sciences, Manchester University NHS Foundation Trust, The University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fiorentino","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine , Redwood City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorinda","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine , Redwood City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1575-9007","authenticated-orcid":false,"given":"Yeong-Wook","family":"Song","sequence":"additional","affiliation":[{"name":"Medical Research Center, Institute of Human-Environment Interface Biology, Department of Internal Medicine, Seoul National University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W","family":"Miller","sequence":"additional","affiliation":[{"name":"Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH , Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Reumatologia, Pediatria II, PRINTO , Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Vencovsky","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, 1st Medical Faculty, Institute of Rheumatology; Charles University , Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Section of Rheumatology at University of Chicago and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh , Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-2458","authenticated-orcid":false,"given":"Lisa G","family":"Rider","sequence":"additional","affiliation":[{"name":"Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH , Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the International Myositis Assessment and Clinical Studies Group (IMACS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Pinal-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Ascherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Schiffenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"2023110720055442400_kead110-B1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2023110720055442400_kead110-B2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"2023110720055442400_kead110-B3","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023110720055442400_kead110-B4","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/rheumatology\/kex226","article-title":"2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects","volume":"56","author":"Rider","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2023110720055442400_kead110-B5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"2023110720055442400_kead110-B6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023110720055442400_kead110-B7","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2023110720055442400_kead110-B8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"Study","year":"2011","journal-title":"Ann Neurol"},{"key":"2023110720055442400_kead110-B9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023110720055442400_kead110-B10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tjarnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023110720055442400_kead110-B11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","article-title":"Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up","volume":"73","author":"Zong","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023110720055442400_kead110-B12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"2023110720055442400_kead110-B13","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2023110720055442400_kead110-B14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/01.bor.0000434667.55020.e1","article-title":"Registries in idiopathic inflammatory myopathies","volume":"25","author":"Lundberg","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"2023110720055442400_kead110-B15","first-page":"349","article-title":"Serum enzyme, myoglobin and muscle strength relationships in polymyositis and dermatomyositis","volume":"13","author":"Kroll","year":"1986","journal-title":"J Rheumatol"},{"key":"2023110720055442400_kead110-B16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead110\/49727021\/kead110.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/11\/3672\/52794563\/kead110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/11\/3672\/52794563\/kead110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T15:19:50Z","timestamp":1699370390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/11\/3672\/7079788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,3,17]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead110","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,3,17]]}}}